82 results about "Nectin" patented technology

The invention belongs to the tissue engineering scaffold field and particularly provides a tissue engineering scaffold containing alginate, glycosaminoglycan and collagen and a preparation method thereof. The tissue engineering scaffold provided by the invention is prepared by the following raw materials by weight percent: 5-30% of chitosan, 5-30% of collagen, 5-30% of alginate, 0.1-3% of hyaluronic acid, 0.01-0.05% of crosslinking agent, 0.1-3% of chondroitin sulfate, 5-20% of polyvinyl alcohol and the balance tertiary distilled water. For optimization, the tissue engineering scaffold also contains a proper amount of cell growth factor, fibronectin and laminin. The tissue engineering scaffold can be processed and shaped and can be used to prepare products with different forms and thickness, the shaping method is easy to operate, the raw materials are easy to get and not expensive and the tissue engineering scaffold can be used for scale industrialized production.

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

The present invention relate for a method for prognosis cancer, in particular metastatic breast cancer comprising doing a dosage of Nectin 4, in a soluble form or in transmembrane form, in a sample, the presence of Nectin 4 being indicative of a cancer.

Cell transplantation for constructing biological heart pacemaker is used embryo source dry / ancestral cell and adult mesogalia dry cell as cell sources. The process is carried out by oriented differentiation inducing for heart pacemaker cell by embryo source multifunctional dry cell, bone marrow adhering to obtain primary culture cell, clone culturing to obtain purifying system by diluting, applying paracrine factor endothelin-1 or nervous adjusting protein-1, extracellular matrix laminated adherent protein and fiber connecting protein etc. substrate glue, trans-dyeing pacemaker gene HCN4, and in-vitro inducing embryo source multifunctional dry cell. It is various and non-immunogenicity. It can be used to treat sick sinus syndrome.

The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.

The invention provides construction and application of a fourth-generation chimeric antigen receptor T (CAR-T) cell (expressing IL-7 and CCL19) specific to Nectin-4 dual targets on the surface of a malignant tumor. Two spatial epitopes of a Nectin-4 antigen are taken as target points, and the constructed fourth-generation CAR-T is used for treating and expressing a malignant solid tumor of the Nectin-4 antigen to solve the immune escape problem of the CAR-T during treatment of the solid tumor; and the constructed fourth-generation CAR-T can enhance proliferative capacity and sustained survivability, so that the solid tumor is effectively treated, and a new strategy is provided for effective prevention and treatment of postoperative recurrence / metastasis of the solid tumor.

Methods for identifying trichogenic dermal cells, including dermal papilla cells and dermal sheath cells, capable of inducing hair follicle formation when injected into skin are provided. It has been discovered that EGF latrophilin and seven transmembrane domain-containing protein 1 (ELTD1). Transmembrane Protein 108 (TMEM1 08), Hyaluronan and proteoglycan link protein 1 (HAPLN1) are biomarkers that can be used to detect, identify, and distinguish trichogenic dermal cells, i.e., that are able to induce hair follicle formation, from other skin cells. Populations of skin cells enriched with trichogenic dermal cells can be produced by selecting for and enriching for dermal cells that express ELTD1, TMEM1 08, HAPLN1, or a combination thereof.

The present disclosure provides compositions and methods for treating or preventing macular degeneration in a subject. The disclosure also provides compositions and methods for preserving organs and tissues for transplantation, and for preventing cellular injury in organs or in subjects.

The invention provides a method for preparing a cell group containing a cytokine-induced killing cell, which comprises the following procedure: a cell group containing a cell which can be differentiated into a cytokine-induced killing cell is cultured in the presence of a fibrous connection protein segment. The invention also provides a cell group which contains the cytokine-induced killing cell obtained by the method. The invention also provides a medicine which contains the cell group as an effective constituent. The invention also provides an application of the cell group to the preparation of medicines.

The invention discloses a culture medium used for culturing adipose mesenchymal stem cells, and applications thereof. The culture medium comprises insulin human, human serum albumin, transferring, fibronectin, ascorbic acid, biotin, PDGF, bFGF, and TGF-beta. It is confirmed by experiments that culturing with the culture medium is capable of obtaining a large amount of high quality mesenchymal stem cells, and the mesenchymal stem cells possess excellent stem cell characteristics, higher immunosuppression activity, and low immunogenicity, and are more suitable to be used for allogeneic cell therapy. The potential risk of clinical applications of exogenous animal serum is avoided, cell pollution rate is reduced, proliferation of human adipose mesenchymal stem cells is promoted, aging speed of human adipose mesenchymal stem cells in in-vitro culture is reduced. Requirements on large scale industrialized production of adipose mesenchymal stem cells needed by clinical therapy are satisfied, and problems such as unstable properties of different batches and high cost are solved at the same time.

The invention provides a human cell junction PDZ protein (CJPDZ) and polynucleotides which identify and encode CJPDZ. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CJPDZ.

The invention discloses a method for detecting interaction between biofilm proteins and a complete set of reagents used by the method. The method for detecting the interaction between biofilm proteinsdisclosed by the invention comprises the following steps of: connecting proteins X and Y to obtain X-Y; connecting proteins YL and R to obtain YL-R, wherein Y and YL interact with each other, and R can drive phase separation to generate phase change liquid drops; connecting XL with a reporter group J to obtain XL-J; introducing an X-Y encoding gene into a biological cell to express the X-Y encoding gene to obtain reconstitution cells, wherein the X-Y is positioned on a biological membrane; adding the YL-R and the XL-J into a culture system of the reconstitution cells, detecting whether signals of the J are gathered in the phase change liquid drops formed by the R or not, and determining whether interaction exists between the X and the XL or not. The method is simple and convenient to operate, high in sensitivity, low in cost and wide in applicability.

The present invention features methods for diagnosing cancer or assessing or determining the prognosis of a patient with lung cancer, by detecting the expression level of Nectin-4. The present invention also features double-stranded molecules against the Nectin-4 gene, vectors encoding them, compositions comprising them and methods comprising the step of administering them into a subject, which are useful for treating or preventing cancer. Also, disclosed are methods of identifying candidate compounds for treating and preventing cancer, using the Nectin-4 polypeptide or cells expressing the Nectin-4 gene.

The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.

The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.

The present invention provides monoclonal antibodies that recognize human Nectin4 with high affinity and specificity and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT).The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.

The invention relates to the technical field of biological tissue engineering, and discloses an organ model construction method based on an organ chip. The organ model construction method comprises the following steps of coating the organ chip; then inoculating cells into first culture micropores and / or second culture micropores; and correspondingly, adding a culture solution into a liquid storage hole and / or a fluid operation hole, and carrying out single-hole culture, co-culture or sequential culture on the cells in the first culture micropores and / or the second culture micropores to obtain the corresponding organ model. According to the embodiment of the invention, on the basis of a specific organ chip, a dynamic culture mode is adopted, external complex equipment is not needed, constant current is realized, the real physiological condition in a body is simulated, and a highly bionic organ model is obtained; the construction mode is flexible, and the construction requirements of different organ models are met; and the constructed organ model has high transmembrane resistance, more tight junction proteins are expressed, and the barrier function is stronger. The invention further discloses the organ model.

The invention provides an Annexin V fluorescent labeling method for detecting early apoptosis of cells. The specific labeling method comprises the following steps: (1) constructing a pET-22b-SNAP-Annexin V gene fusion plasmid vector; (2) performing prokaryotic expression and purifying pET-22b-SNAP-Annexin V fusion protein; and (3) labeling the fusion protein by using fluorescent small molecules and performing purification. Annexin V protein is one of best phosphatidylserine (PS) binding receptors found at present, shows high selectivity and high binding ability for PS binding, and fluorescently labeled AnnexinV is one of most commonly used reagents for detecting the early apoptosis of the cells. The invention creates the novel method of Annexin V fluorescent labeling, firstly, SNAP tag protein and the Annexin V protein are fused, expressed and purified through the genetic engineering method, then a small molecule fluorescent probe connected to a BG group of a special substrate of the SNAP protein is used to label the fusion protein and label the Annexin V, and the apoptotic cells are detected by cell imaging or flow cytometry. The method has important significance for the researchof the cell apoptosis process.

The invention relates to use of axitinib and an analogue thereof in preparation of a blood-brain barrier permeability regulating agent. The blood-brain barrier permeability regulating agent can reducethe blood-brain barrier permeability and promote the recovery of a blood-brain barrier function from a pathological damage state to an approximate physiological barrier state. The axitinib and the analogue thereof, by suppressing vascular endothelial cell growth factor-phosphatidylinositol kinase-protein kinase B signaling pathway, can reduce the down-regulating degree of pathological blood brainbarrier tightly attached protein Claudin-5 / Occludin and reduce the blood-brain barrier permeability. The blood-brain barrier permeability regulating agent can be used for treatment of related diseases that cause changes in the blood-brain barrier permeability.

The invention provides a construction method for an escherichia coli infected monolayer compact bovine mammary epithelial cell model. The cell model is a monolayer compact bovine mammary epithelial cell model infected with escherichia coli is ATCC 25922, and during infection, the transepithelial electrical resistance value of the monolayer compact bovine mammary epithelial cell is 400 [omega]. cm<2>. The escherichia coli infected monolayer compact bovine mammary epithelial cell model provided by the invention can be used for detecting the adhesion rate of the escherichia coli infected monolayer compact bovine mammary epithelial cell and an influence of the escherichia coli infected monolayer compact bovine mammary epithelial cell for the expression of bovine mammary epithelial cell tight junction protein, and can be widely applied to related fields, including the screening of an injury mechanism of the escherichia coli induced mastitis for mammary tissues and mammary epithelial cells,and an antibiotic substitute.

The invention provides a recombinant S protein, a recombinant plasmid and a recombinant bacterium of a novel coronavirus and application of the recombinant S protein, the recombinant plasmid and the recombinant bacterium in preparation of an exosome drug or an exosome vaccine, and relates to the technical field of vaccines. According to the invention, the recombinant S protein comprises a subunit S1 and a subunit S2 of a spike protein S; the S1 protein and the S2 protein are connected through utilizing a linker to form the recombinant S protein; all the components are mutually coordinated and supplemented; and the recombinant S protein has good immunogenicity, safety and biological activity and can induce an organism to generate an effective antibody, so that the growth of the novel coronavirus is inhibited, and the infection of the novel coronavirus can be effectively prevented. According to the invention, the recombinant S protein is electrically transferred into an exosome by adopting an artificial exosome carrying form, so that the pharmacokinetic and pharmacodynamic characteristics of a carried therapeutic agent can be improved, thereby enhancing the therapeutic effect and meanwhile, reducing the adverse toxicity and side effects; and the recombinant S protein has wide cell adhesion molecules and is beneficial for penetrating a biological barrier.

Methods for diagnosing Alzheimer's Disease by detection of fragments of nectin-1 are described. Nectin-1 is shown to be a substrate for proteases associated with the onset of Alzheimer's Disease, including α-secretase, γ-secretase and BACE1 or a BACE1-like protease. The fragments produced by the action of these and other proteases on Nectin-1 can be used to diagnosis Alzheimer's Disease or a predilection towards Alzheimer's Disease.

The invention provides polypeptides comprising isolated domains of Necl proteins, particularly of Necl4, that mediate axon-glia adhesion required for myelination. The invention further provides pharmaceutical compositions comprising as the active ingredient a polypeptide comprising an isolated Necl4 domain, or a polynucleotide encoding a polypeptide comprising an isolated Necl4 domain. Further provided are antibodies directed against isolated Necl domains, siRNA capable of down regulating Necl4 expression, and methods for treating neurological disorders which are associated with aberrant myelination.

The invention discloses effect of connexin Panx1 in preparation of a medicine for preventing and treating neuropathic pain, and belongs to the technical field of biological medicines. Main expression Panx1 in Schwann cells is determined, and the expression quantity of the Panx1 can be remarkably increased due to chronic neuropathic pathological injury; an inhibitor and a mimic peptide of the Panx1 can remarkably inhibit mechanical pain and heat pain caused by chronic neuropathic pathological injury of sciatic nerves, and meanwhile, a Panx1 inhibitor probenecid can remarkably inhibit the expression of the Panx1 caused by injury. Therefore, powerful basic research evidence is provided for treating patients with chronic neuropathic pathological pain by clinically utilizing the Panx1 inhibitor in the future.

The invention relates to the field of medical biology, and provides a separation and amplification method and application of human dental pulp stem cells. The separation and amplification method comprises the following steps: S1, taking human dental pulp tissue, cutting the human dental pulp tissue into pieces, and adding collagenase I, hyaluronidase and dispase II for digestion to obtain digestedtissue and cell suspension; S2, filtering the digested tissue and cell suspension by using a filter screen, centrifuging the filtrate, and taking cell precipitate to obtain human dental pulp stem cells; and S3, inoculating the human dental pulp stem cells into a culture dish pre-coated with human fibronectin, adding a culture solution for culture, and performing subculture when convergence rate reaches 70-80%. The method has a short time for cell adherence, number of cells cultured to the 10th day of at least 4.5x105, high cell purity, positive expression rate of dental pulp stem cell surfacemarkers CD73, CD90 and CD105 above 99%, and negative index expression rate lower than 1.2%.

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

The present invention relates to diagnostic and prognostic methods and kits for assessing chronic inflammation and associated immune-suppression. More particularly, the invention relates to the use of SNX9 (sorting nexin 9 protein) as a biomarker for chronic inflammation and associated immune-suppression, specifically, in subjects suffering from chronic inflammatory conditions. The invention further provides a prognostic tool for detecting regression or recurrence of the diseases and a powerful tool for assessing efficacy of a treatment. The present invention further provides SNX9 as an immunomodulator and therefore relates to methods for treating immune-related disorders by modulating SNX9 expression.

The invention provides application of an exosome derived from mesenchymal stem cells in preparation of a medicine for treating acute lung injury caused by sulfur mustard. The invention particularly relates to separation of bone marrow mesenchymal stem cell supernate to obtain exosomes and application of the exosomes to acute lung injury caused by sulfur mustard. The exosomes can significantly improve survival rate of experimental animals and improve activity of lung cells under the exposure of sulfur mustard, improves changes in lung tight junction proteins caused by sulfur mustard, and resists lung injury effect of sulfur mustard. Therefore, the invention provides a new treatment approach for acute lung injury caused by sulfur mustard.

The present invention relates to multispecific binding proteins targeting CAIX, ANO1, mesothelin, TROP2, or a claudin-18.2. In particular. Specifically, the present invention describes multispecific binding proteins that bind to the NKG2D receptor, CD16 and a tumor-associated antigen selected from the group consisting of carbonic anhydrase 9 (CAIX), calcitonin 1 (ANO1), mesothelin, TROP2, CEA and claudin-18.2, as well as pharmaceutical compositions and methods of treatment useful in the treatment of cancer.